A month has gone by since the last earnings report for Inovio Pharmaceuticals (INO - Free Report) . Shares have lost about 36.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Inovio due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Inovio Q1 Earnings & Revenues Fall Short of Estimates
Inovio incurred a loss of 30 cents per share for the first quarter of 2019, wider than the Zacks Consensus Estimate of a loss of 29 cents but narrower than the year-ago loss of 36 cents.
Inovio generated revenues of $2.8 million in the reported quarter, missing the Zacks Consensus Estimate of $4.4 million. Revenues soared 86.6% from the year-ago quarter’s figure of $1.5 million owing to the milestone payment received from AstraZeneca in the quarter under a collaboration agreement for MEDI0457.
Research and development expenses slipped marginally 0.8% to $24.4 million due to absence of a sub-license expense incurred in the year-ago quarter in connection with the ApolloBio collaboration.
General and administrative expenses decreased 27.8% to $7 million in the quarter owing to the lower foreign non-income taxes and advisory fees.
How Have Estimates Been Moving Since Then?
Fresh estimates followed an upward path over the past two months.
Currently, Inovio has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Inovio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.